![](/img/cover-not-exists.png)
Thalidomide reduces serum C-reactive protein and interleukin-6 and induces response to IL-2 in a fraction of metastatic renal cell cancer patients who failed IL-2-based therapy
Igal Kedar, Wilmosh Mermershtain, Hefziba IvgiVolume:
110
Year:
2004
Language:
english
Pages:
6
DOI:
10.1002/ijc.20089
File:
PDF, 341 KB
english, 2004